CASTELLETTI, SEFORA
 Distribuzione geografica
Continente #
NA - Nord America 476
EU - Europa 251
AS - Asia 49
Continente sconosciuto - Info sul continente non disponibili 1
OC - Oceania 1
Totale 778
Nazione #
US - Stati Uniti d'America 474
SE - Svezia 59
UA - Ucraina 56
IT - Italia 52
DE - Germania 26
DK - Danimarca 19
IE - Irlanda 18
TR - Turchia 16
SG - Singapore 15
KR - Corea 11
FI - Finlandia 10
GB - Regno Unito 7
CN - Cina 5
NL - Olanda 3
MX - Messico 2
AU - Australia 1
EU - Europa 1
JP - Giappone 1
PK - Pakistan 1
RO - Romania 1
Totale 778
Città #
Chandler 119
Jacksonville 62
Fairfield 41
Ann Arbor 20
Wilmington 20
Woodbridge 20
Dublin 18
Lawrence 17
Princeton 17
Seattle 16
Ashburn 15
San Mateo 13
Des Moines 12
Redmond 12
Centro 11
Ancona 10
Houston 9
Cambridge 7
Napoli 7
San Diego 4
Beijing 3
Boardman 3
Marche 3
Salerno 3
Amsterdam 2
Cameri 2
Monterrey 2
Nanjing 2
Norwalk 2
San Severino Marche 2
Adelaide 1
Chiaravalle 1
Esanatoglia 1
Helsinki 1
Islamabad 1
Kagoya 1
London 1
Los Angeles 1
Mcallen 1
Milan 1
Montesilvano 1
Nürnberg 1
Palermo 1
Porto 1
San Benedetto Del Tronto 1
Suceava 1
Totale 490
Nome #
Protective effects of the combination alpha-helical antimicrobial peptides and rifampin in three rat models of Pseudomonas aeruginosa infection 80
Spread of colistin resistance gene mcr-1 in Italy: characterization of the mcr-1.2 allelic variant in a colistin-resistant blood isolate of Escherichia coli 74
Clinical and epidemiological characteristics of KPC-producing Klebsiella pneumoniae from bloodstream infections in a tertiary referral center in Italy 57
Protective effects of the combination of alpha-helical antimicrobial peptides and rifampicin in three rat models of Pseudomonas aeruginosa infection. 54
In vitro susceptibility of dermatophytes to conventional and alternative antifungal agents. 52
In vitro activity of the lipopeptide derivative (Pal-Lys-Lys-NH), alone and in combination with antifungal agents, against clinical isolates of dermatophytes. 50
Efficacy and costs of Direct Acting Antivirals (DAAS) for the treatment of HCV Iinfection amnog HCV-monoinfected and HIV/HCV co-infected patients in real-life setting 50
La resistenza agli antibiotici in Pseudomonas aeruginosa: studio molecolare ed epidemiologico in un nosocomio marchigiano 49
null 47
Therapy with direct-acting antiviral agents in transplanted patients with HCV recurrence: a retrospective analysis 46
Direct acting antivirals (DAAs) for the treatment of HCV infection in HIV/HCV coinfected patients: a clinical experience. 43
In vitro activity of the lipopetide derivative (Pal-lys-lysNh2), alone and in combination with antifungal agents, against clinical isolates of dermatophytes 40
Protective effects of the combination alpha-helical antimicrobial peptides and rifampin in three rat models of Pseudomonas aeruginosa infection. 30
Use of dalbavancin in skin, bone and joint infections: A real-life experience in an Italian center 29
Economic Consequences of Investing in Anti-HCV Antiviral Treatment from the Italian NHS Perspective: A Real-World-Based Analysis of PITER Data 26
Bloodstream infections in the COVID-19 era: results from an Italian multi-centre study 23
Clinical features and comorbidity pattern of HCV infected migrants compared to native patients in care in Italy: A real-life evaluation of the PITER cohort 23
Clinical and microbiological features of ceftolozane/tazobactam-resistant Pseudomonas aeruginosa isolates in a university hospital in central Italy 19
Antiretroviral therapy management and rationalisation of available resources 15
Totale 807
Categoria #
all - tutte 2155
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 2155


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2017/201827 0000 00 00 41670
2018/201935 19000 112 10 0101
2019/2020105 20101 160 121 1627614
2020/2021162 1217233 156 305 188214
2021/2022137 43118 32 1410 1251433
2022/2023274 25353021 3037 125 70000
Totale 807